Taiwan Mask Corporation

Taiwan Mask Corporation is Taiwan's only listed specialist photomask maker. It was founded in 1988 alongside TSMC and UMC as part of the ITRI spin-off wave that built the island's chip industry. Photomasks are the quartz "negatives" a wafer fab uses to expose circuit patterns, and TMC sells them as a merchant (independent) supplier. Its sweet spot is mature and mid-range logic, power, analog and specialty nodes. It began on 0.35 µm and 0.18 µm masks for 6-inch and 8-inch fabs and has moved up to 12-inch masks at 90/80/65/55 nm, with 40 nm in volume ramp and 28 nm in customer qualification. Its customers are leading Taiwanese and Korean foundries and IDMs. For about a decade TMC expanded into a loose group of subsidiaries covering memory packaging, touch-controller ICs, precision coating, energy and medical devices. Those businesses dragged the group to record losses in 2025. Since Star Fusion (then Softstar) bought 20% in July 2025, TMC has been divesting, closing or spinning off non-core units. It is putting the proceeds into 12-inch mid-range capacity and a 14-inch large-format mask line for 2.5D/3D advanced-packaging interposers, and it is entering semiconductor equipment services in Kyushu, Japan.

What the company does. TMC researches, develops, manufactures and sells photomasks. It also provides technical assistance, consulting, inspection, maintenance and repair services for those products. Its business registration also covers steel-structure welding and machinery manufacturing, reflecting the laser-welding activity later spun into a separate subsidiary. The consolidated group (TMC and subsidiaries) has also made and sold integrated circuits, provided precious-metal coating, 3D printing and plastic-mould design, packaging and testing, power-component design, energy technical services, and medical-equipment manufacturing and distribution.

The company's own description. The latest financial statements describe the group's main activities as the research, development, manufacture and sale of photomasks and integrated circuits; technical assistance, consulting, inspection and repair services for those products; and the manufacture and trade of medical equipment.

Independent characterisation. In economic terms TMC is a single-product merchant mask shop inside a holding structure that is being simplified. Revenue is almost entirely product revenue: each photomask is custom-made to a customer's design and sold per mask or per mask set. There is no material subscription or licensing income. Data-preparation services such as mask rule checks, remote job-deck viewing (JDV) and CAD layout services are part of the order flow rather than a separate revenue line. On a parent-only basis, photomask products make up about 96% of sales and other operating units about 4%. At the consolidated level, the core mask business was roughly 60% of group revenue in early 2026. Parent revenue of NT$3,615 million in FY2025 was 59.9% of consolidated revenue of NT$6,038 million.

Value-chain position. TMC sits between IC design and wafer fabrication. A finished chip design must be turned into a mask set before the fab can expose wafers, so mask orders lead foundry wafer starts and are an early signal of turns in the foundry cycle. Upstream, TMC buys mask blanks (mainly from Japanese makers) and e-beam and laser writers, inspection and repair tools. Downstream, it supplies foundries, IDMs and fabless designers that order masks for mature-node tape-outs.

Customer types and end-markets. Disclosed and reported customers include TSMC, Vanguard International Semiconductor, DB HiTek (Korea), UMC, GlobalFoundries and WIN Semiconductors. End-markets are the mature-node and specialty segments: power management, display drivers, MCUs, CMOS image sensors, analog/mixed-signal, compound-semiconductor RF, automotive and industrial chips. The 14-inch line now being installed targets CoWoS-class silicon interposers and bump layers for AI and high-performance-computing packages.

Revenue model mix.

Photomask products: Share of parent revenue (latest): 96.1; Comment: Custom binary and phase-shift masks; per-mask pricing

Other operating units: Share of parent revenue (latest): 3.9; Comment: Services, laser welding and other activities before spin-off

Stated strategy. Since the change of control, management's message has been the same throughout: "focus on the core photomask business". In practice that means:

1. Moving up the node ladder in 12-inch masks. Raise utilisation and output in 55–90 nm, put 40 nm into volume production in 2H 2026, and invest step by step in 28 nm, with qualification targeted by end-2026 and revenue in 2027.

2. Advanced-packaging masks. Build 14-inch large-format mask capacity for important customers' 2.5D/3D interposer needs. NT$435 million has been committed to core equipment, and AI-related capex is put at NT$300–400 million in total.

3. Subsidiary restructuring. Reorganise each subsidiary according to its competitive strengths through spin-offs, mergers or strategic investors, and exit low-return businesses.

4. Putting idle assets to work. Convert under-used property (Zhunan Fab 6) into cash for core capacity and debt reduction.

5. Expanding into Japan. Use T.C.K. in Kumamoto to provide local equipment-engineering support to Taiwanese and Japanese chip customers in the "Silicon Island Kyushu" cluster.

Initiatives in the last 24 months

Jul 2025: Initiative: Strategic private placement; Detail: NT$1.546 billion from Softstar/Star Fusion at NT$24.4 per share

Jun 2025: Initiative: Exit from memory packaging; Detail: Aptos dissolved; NT$83 million loan waived

Oct 2025: Initiative: Laser-welding spin-off; Detail: Taiwan Laser Welding Technology set up with NT$270 million of contributed equipment

Oct 2025: Initiative: Moment Semiconductor restructuring; Detail: Strategic investors from Star Fusion's group join a capital increase; TMC drops to 25.27% and deconsolidates

Nov 2025: Initiative: Hydrogen spin-off; Detail: Magpie Energy created from Pilot Energy

Dec 2025–Jan 2026: Initiative: Innova Vision fundraising; Detail: About NT$193 million raised from outside investors to expand silicone-hydrogel and coloured lenses and build an own brand

Jan–Mar 2026: Initiative: NT$1.75 billion capital increase; Detail: Funds the "process upgrade and capacity expansion plan" for 28 nm-and-above masks and 14-inch masks

Jun 2026: Initiative: Zhunan Fab 6 sale; Detail: NT$2.8 billion; expected pre-tax gain NT$1.824 billion

Jun 2026: Initiative: 光鉅控股 capital increase; Detail: New cash equity raised at the holding subsidiary

Jul–Oct 2026: Initiative: Japan acquisition; Detail: LOI for up to JPY1 billion, then a definitive JPY750 million deal for T.C.K.

Medium-term targets and guidance. For 2026, management guides to core photomask revenue growth of 10–20%; later statements gave a range of about 10–25%. Growth is to come from added 40/65/90 nm capacity and 28 nm qualification. Large-format masks are expected to reach about 10% of revenue in 2027. The 2023 ambition of US$1 billion in group revenue has not been repeated since the restructuring. At the parent level, Star Fusion has said it expects TMC to return to profit in 2026 and that its own group revenue will exceed NT$10 billion in 2026, with semiconductors and power about 90% of the mix.

Photomask products (core)

Photomask data and engineering services

Non-core group offerings

Pricing is quoted per mask according to node, layer criticality, substrate size and turnaround time. Prices for individual products are not publicly disclosed.

All figures are consolidated, in NT$ million unless stated, under Taiwan-IFRS, from the audited annual financial statements for each fiscal year (FY = calendar year). Net income is attributable to owners of the parent.

Income statement

Margins

Revenue fell at a compound annual rate of 0.2% from FY2021 to FY2025 (NT$6,077 million to NT$6,038 million). The FY2025 figure hides two opposite trends. The parent mask business kept running at high utilisation, while consolidated revenue shrank as Aptos, Xsense and other subsidiaries were wound down or deconsolidated.

Commentary: income statement. FY2021–FY2022 was the up-cycle peak. Mature-node mask outsourcing by foundries and the 2021 chip shortage pushed gross margin to 27.1% and operating margin to 16.1% in FY2022. FY2021 net income of NT$1,147 million exceeded operating income because of large non-operating gains. From FY2023, gross margin fell steadily for three reasons. First, depreciation more than doubled from NT$608 million (FY2022) to NT$1,519 million (FY2025) as 12-inch capacity came on line. Second, Chinese mask makers competed hard on price in mature nodes. Third, low-margin, loss-making subsidiaries diluted the mix. FY2025 was the worst year in the company's history. Revenue fell 20% to a five-year low, the operating loss of NT$608 million was a record, and non-operating losses of NT$895 million (impairments, the Aptos write-down and investment losses) produced a parent net loss of NT$1,174 million, or NT$4.88 per share. Management blamed geopolitically driven supply-chain realignment, tougher Chinese competition and a weak cycle, made worse by shrinking subsidiaries.

Quarterly trajectory (NT$ million)

The 0 values for Q1–Q3 2025 earnings and Q3 2026 earnings are placeholders, not results. The cumulative Q1–Q3 2025 parent net loss was NT$811 million (EPS –3.56), and Q3 2026 earnings had not yet been released at the time of writing. Q3 2026 revenue comes from monthly sales filings. Q1 2026 ended seven straight quarterly losses: operating income was NT$14 million and parent net income NT$149 million (EPS 0.52). First-half 2026 parent net income was NT$185 million (EPS 0.61), which puts Q2 2026 EPS at about NT$0.09. The Q2 announcement headline showed NT$0.12 on a different share-count basis. The NT$1.824 billion pre-tax gain on the Zhunan Fab 6 sale is booked in Q3 2026, after the 9 September 2026 transfer. On the share count before the 2026 capital increase, that gain is worth about NT$6.38 pre-tax per share.

Balance sheet (year end, NT$ million)

At 30 June 2026 total assets were NT$18,365 million, cash NT$1,556 million, total debt NT$9,621 million (short-term NT$4,382 million, current long-term NT$1,605 million, long-term NT$3,235 million) and parent equity NT$6,269 million. The improvement reflects the NT$1.75 billion capital increase completed in March 2026. In the FY2025 audit report, PwC highlighted a 75% debt ratio and a 63% current ratio at 31 December 2025 and referred to management's operational improvement plan.

Cash flow (NT$ million)

Commentary: balance sheet and cash flow. From FY2021 to FY2024 the company spent NT$10 billion on capex. That paid for its move into 12-inch masks and the subsidiary expansion, and it was funded mostly with bank debt, as total debt rose from NT$9.4 billion to NT$14.6 billion. Dividends and NT$1.67 billion of buybacks were maintained along the way. Working capital turned negative in FY2022 and stayed negative. Free cash flow was negative for four straight years. FY2025 was the first year of balance-sheet repair. Capex was cut to NT$1.3 billion, operating cash flow reached a five-year high of NT$2.4 billion as working capital was released from shrinking subsidiaries, and NT$3.2 billion of net debt was repaid using the NT$1.546 billion private placement. In 2026 the NT$1.75 billion cash capital increase and the NT$2.8 billion Zhunan proceeds should cut net debt further, possibly to roughly a third of its FY2024 peak by year-end 2026 if no new large commitments are made.

Ratios

Commentary: ratios. Returns peaked in FY2021–FY2022 and turned negative in FY2024. Leverage was the main weakness: net debt was 8.7 times EBITDA in FY2024 and 12.1 times in FY2025, and interest coverage fell below 1x in FY2024. The current ratio has been below 1.0 since FY2022, reflecting heavy reliance on short-term bank lines. Asset turnover of about 0.35x is structural for a capital-intensive mask maker, but returns at this turnover depend on gross margins in the mid-20s, which the company has not reached since FY2023. Operating days for receivables, inventory and payables, and therefore the cash conversion cycle, are not publicly disclosed in summary form.

Management guidance. Management guides to double-digit core mask revenue growth in 2026, about 10–20% and in later statements 10–25%. That is to come from 40 nm volume production in 2H 2026, first 14-inch large-format revenue in Q4 2026, and 28 nm qualification by year-end with revenue from Q1 2027. Large-format masks are targeted at about 10% of revenue in 2027. Consolidated revenue for the first nine months of 2026 was NT$4.541 billion, down 2.7%, with September up 15.4% year on year. The gap between core growth and group revenue reflects subsidiary exits.

Bull case

1. Core recovery is already visible. The parent returned to operating profit in Q1 2026, with core mask revenue above 60% of the group and utilisation above 90%. A 28 nm and 14-inch mix shift could lift gross margin back toward the 25%+ levels of FY2022–FY2023.

2. The balance sheet is being rebuilt quickly. NT$1.546 billion (2025) plus NT$1.75 billion (2026) of new equity and NT$2.8 billion from Zhunan add up to about NT$6.1 billion. Against FY2025 net debt of NT$10.5 billion, that could roughly halve leverage and save a large part of the NT$306 million annual interest bill.

3. Hidden assets. The 13.5 million Luxnet shares bought at NT$30.4 were worth several times cost at June 2026 prices, if fully retained. The T.C.K. acquisition adds a cash-generating Japanese business for only about NT$160 million.

Bear case

1. 2026 earnings are mostly one-off. The Zhunan gain of about NT$1.82 billion is roughly ten times first-half recurring net income of NT$185 million.

2. Structural margin gap. At a 7.8% gross margin in FY2025, against about 35% at Photronics, TMC competes on price against Chinese mature-node mask makers. The node migration may only restore parity with weaker peers.

3. Execution and governance risk. New capacity has already been delayed, R&D spending fell 16%, and the board seats are split between the controlling shareholder and an industrial investor. The controlling shareholder's history is roll-up M&A, which could bring back the diversification that caused the 2025 losses.

Key catalysts (next 12 months)

Mid-Nov 2026: Catalyst: Q3 2026 results, including the Zhunan gain

Q4 2026: Catalyst: First 14-inch large-format mask revenue

End-2026: Catalyst: 28 nm customer qualification result

29 Dec 2026: Catalyst: Investor conference

Q4 2026–Q1 2027: Catalyst: Closing and consolidation of T.C.K.

Mar 2027: Catalyst: FY2026 results and dividend decision

Q1 2027: Catalyst: First 28 nm revenue

Monthly: Catalyst: Revenue prints, to see whether year-on-year growth holds after the subsidiary base effect fades

Monitorables. Quarterly gross margin (whether it rises above 20%), net debt after the Zhunan proceeds, the share of 12-inch and 14-inch masks in the mix, any new non-core acquisitions by the controlling group, and Chinese mask pricing.

Analyst verdict. Taiwan Mask Corporation enters 2027 as a much simpler company than it was two years ago. For most of the past decade it spread its capital across memory packaging, touch ICs, energy, coatings and contact lenses while its core mask business moved, with difficulty, from 8-inch to 12-inch. The result was a debt-funded capex cycle, negative free cash flow every year from FY2021 to FY2024, net leverage above eight times EBITDA, and a record FY2025 loss of NT$4.88 per share. The new owner did not change the industrial logic of the core business, but it did change the capital allocation. Within roughly fifteen months the group exited Aptos, deconsolidated or spun off several units, raised more than NT$3.3 billion of equity, and turned an under-used fab into NT$2.8 billion of cash. These steps address the balance-sheet problems the auditor flagged at end-2025.

Whether the underlying business can earn adequate returns is less settled. Twelve-inch masks now dominate the mix and run near full utilisation, 40 nm is qualified, and the 14-inch interposer line gives TMC a small, credible link to AI-driven advanced packaging. Yet TMC remains a sub-scale, mature-node merchant whose gross margins trail global peers by more than 25 points and whose main competitive threat, Chinese overcapacity, will not go away. The roughly NT$1.8 billion property gain in 2026 will flatter reported earnings and could support a resumed dividend, but it says nothing about recurring profitability.

At about 2.7 times book and near 29 times trailing EBITDA, the market already prices in much of the turnaround. The investment case rests on three verifiable milestones: 28 nm qualification by year-end, meaningful 14-inch revenue in 2027, and gross margin back above 20%. Delivery on all three would support the current re-rating. Slippage on any of them, or a return to scattered acquisitions, would expose a valuation that is ahead of the fundamentals. On balance, TMC is a credible but still early-stage turnaround: execution-dependent, cyclical, and best judged on recurring core margins rather than headline earnings.